Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma

NCT04405167 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT04405167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04405167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refractory Myeloma
Lead sponsor
University of Pennsylvania
Phase
Phase 1
Overall status
Terminated
Start date
July 10, 2020
Completion date
July 1, 2025
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma